Benzinga | Nov 9, 2021 11:02AM EST

Avita Therapeutics Q1 EPS $(0.24) Beats $(0.38) Estimate, Sales $7.00M Miss $7.10M Estimate

Avita Therapeutics (NASDAQ:RCEL) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.38) by 36.84 percent. This is a 50 percent increase over losses of $(0.48) per share from the same period last year. The company reported quarterly sales of $7.00 million which missed the analyst consensus estimate of $7.10 million by 1.41 percent. This is a 38.34 percent increase over sales of $5.06 million the same period last year.